When Gilead acquired CAR-T leader Kite Pharma, it made a crucial decision not to fully integrate it. This preserved Kite's distinct, individualized therapy operating model, which is fundamentally different from a traditional "off-the-shelf" drug company, proving a key lesson in M&A strategy for novel platforms.

Contrary to seeking fully de-risked assets, pharmaceutical companies often prefer acquiring companies with some remaining clinical risk. This strategy allows them to leverage unique insights on early data to acquire assets at a better valuation, creating an opportunity for outsized returns before the value is obvious to others.

After years of focusing on de-risked late-stage products, the M&A market is showing a renewed appetite for risk. Recent large deals for early-stage and platform companies signal a return to an era where buyers gamble on foundational science.

In a creative maneuver, Gilead is acquiring T-cell developer Oro while arranging for its partner, Galapagos (in which Gilead owns a 25% stake), to integrate Oro's team and co-fund development. This allows Gilead to leverage Galapagos's balance sheet to execute its own strategic acquisition.

Gilead's acquisition of Arcellx includes a CVR, promising an extra $5 per share if the drug anita-cel hits a $6B sales target by 2029. This structure mitigates upfront risk for Gilead while allowing Arcellx shareholders to benefit from future commercial success, aligning incentives post-acquisition.

Gilead is betting it can overcome the manufacturing and supply chain challenges that have limited J&J's successful Carvykti therapy. While Arcellx's AnitoCell shows similar efficacy, justifying the premium price tag depends on delivering a more reliable and scalable manufacturing process, which remains unproven.

Observing that allogeneic ('off-the-shelf') cell therapies have not yet achieved their expected impact, Kite Pharma is strategically investing in in vivo approaches. Through acquisitions and partnerships, they are focusing on technologies that edit cells directly within the body, which have shown promising 'autologous-like' results.

With patent cliffs looming and mature assets acquired, large pharmaceutical companies are increasingly paying billion-dollar prices for early-stage and even preclinical companies. This marks a significant strategic shift in M&A towards accepting higher risk for earlier innovation.

Gilead timed its acquisition of Arcelix to capitalize on peak investor sentiment and a surging stock price, which were driven by its successful HIV franchise. This allowed the company to strategically bolster its smaller oncology pipeline from a position of financial and market strength.